EnteroMedics Inc. (NASDAQ:RSLS) posted its quarterly earnings results on Tuesday. The medical device company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.77), Bloomberg Earnings reports. EnteroMedics had a negative net margin of 4,399.48% and a negative return on equity of 167.73%.
EnteroMedics (NASDAQ RSLS) traded down $0.05 during trading hours on Tuesday, hitting $1.65. 217,000 shares of the company were exchanged, compared to its average volume of 1,693,029. EnteroMedics has a 1 year low of $1.47 and a 1 year high of $30.41.
RSLS has been the subject of several analyst reports. Zacks Investment Research cut shares of EnteroMedics from a “buy” rating to a “hold” rating in a research note on Thursday, July 20th. ValuEngine raised shares of EnteroMedics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
EnteroMedics Company Profile
ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.
Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.